Bisphosphonate-related osteonecrosis of the jaws: How to manage cancer patients

Oral Oncology

Volumn 46, Issue 6, 2010, Pages 468-470

  Madrid, C ^a   Bouferrache, K ^a   Abarca, M ^a   Jaques, B ^b   Broome, M ^b  

^a Department of Ambulatory Care and Community Medicine   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Osteoradionecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN; COLLAGEN TELOPEPTIDE; PAMIDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

APOPTOSIS; BONE PAIN; BONE SCINTISCANNING; CANCER PATIENT; CONSERVATIVE TREATMENT; DENTURE; DIAGNOSTIC IMAGING; HUMAN; HYPERBARIC OXYGEN; HYPERCALCEMIA; JAW OSTEONECROSIS; MOUTH MUCOSA; MUCOSA CELL; OSTEOCLAST; PATHOGENESIS; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; TOOTH EXTRACTION; WOUND HEALING;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; JAW DISEASES; MALE; OSTEONECROSIS; RISK FACTORS;

EID: 77952742243     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.03.016     Document Type: Review

References (34)

1. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 9 Suppl. 4 (2004) 14-27
2. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 8 (2003) 1735-1744
3. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 11 (2004) 879-882
4. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21 16 (2003) 3150-3157
5. Madrid C., and Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res 20 Suppl. 4 (2009) 87-95
6. Ruggiero S.L., Dodson T.B., Assael L.A., Landesberg R., Marx R.E., Mehrotra B., and American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 67 Suppl. 5 (2009) 2-12
7. Walter C., Al-Nawas B., Grötz K.A., Thomas C., Thüroff J.W., Zinser V., et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54 5 (2008) 1066-1072
8. Allen M.R., and Burr D.B. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67 Suppl. 5 (2009) 61-70
9. Landesberg R., Cozin M., Cremers S., Woo V., Kousteni S., Sinha S., et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66 5 (2008) 839-847
10. Sarasquete M.E., González M., San Miguel J.F., and García-Sanz R. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 15 6 (2009) 382-387
11. Vahtsevanos K., Kyrgidis A., Verrou E., Katodritou E., Triaridis S., Andreadis C.G., et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27 32 (2009) 5356-5362
12. Kyrgidis A. Novel hypotheses in the etiopathogenesis of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67 11 (2009) 2554
13. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 6 (2008) 826-836
14. Estilo C.L., Van Poznak C.H., Wiliams T., Bohle G.C., Lwin P.T., Zhou Q., et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 13 8 (2008) 911-920
15. Arce K., Assael L.A., Weissman J.L., and Markiewicz M.R. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg 67 Suppl. 5 (2009) 75-84
16. Schauwecker D.S. The scintigraphic diagnosis of osteomyelitis. AJR Am J Roentgenol 158 1 (1992) 9-18
17. Chiandussi S., Biasotto M., Dore F., Cavalli F., Cova M.A., and Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 35 4 (2006) 236-243
18. Pautke C., Bauer F., Bissinger O., Tischer T., Kreutzer K., Steiner T., et al. Tetracycline bone fluorescence: a valuable marker for osteonecrosis characterization and therapy. J Oral Maxillofac Surg 68 1 (2010) 125-129
19. Pautke C., Bauer F., Tischer T., Kreutzer K., Weitz J., Kesting M., et al. Fluorescence-guided bone resection in bisphosphonate-associate osteonecrosis of the jaws. J Oral Maxillofac Surg 67 3 (2009) 471-476
20. Bisdas S., Chambron Pinho N., Smolarz A., Sader R., Vogl T.J., and Mack M.G. Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 63 1 (2008) 71-77
21. Rosen H.N., Moses A.C., Garber J., Iloputaife I.D., Ross D.S., Lee S.L., et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66 2 (2000) 100-103
22. Fink E., Cormier C., Steinmetz P., Kindermans C., Le Bouc Y., and Souberbielle J.C. Differences in the capacity of several biochemical bone markers to assess high bone turnover in earl menopause and response to alendronate therapy. Osteoporos Int 11 4 (2000) 295-303
23. Schwartz H.C. Serum CTX testing. J Oral Maxillofac Surg 66 6 (2008) 1319-1320
24. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw, Khosla S., Burr D., Cauley J., Dempster D.W., et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CT testing, prevention, and treatment. J Oral Maxillofac Surg 66 6 (2008) 1320-1321
25. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 12 (2007) 2397-2410
26. Kwon Y.D., Kim D.Y., Ohe J.Y., Yoo J.Y., and Walter C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67 12 (2009) 2644-2648
27. Bagan J.V., Jiménez Y., Gómez D., Sirera R., Poveda R., and Scully C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 44 11 (2008) 1088-1089
28. Uebelhart B., and Rizzoli R. Trends in osteoporosis. Rev Med Suisse 4 140 (2008) 144-146 148-9
29. Dimopoulos M.A., Kastritis E., Bamia C., Melakopoulos I., Gika D., Roussou M., et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20 1 (2009) 117-120
30. Ripamonti C.I., Maniezzo M., Campa T., Fagnoni E., Brunelli C., Saibene G., et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20 1 (2009) 137-145
31. Madrid C., Jaques B., Bouferrache K., and Broome M. Management of complications of bisphosphonates in oncology patients: jaw osteonecrosis. Rev Med Suisse 3 112 (2007) 1322 1324-6, 1329-31
32. Lodi G., Sardella A., Salis A., Demarosi F., Tarozzi M., and Carrassi A. Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 68 1 (2010) 107-110
33. Freiberger J.J. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67 Suppl. 5 (2009) 96-106
34. Carlson E.R., and Basile J.D. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67 Suppl. 5 (2009) 85-95